AbbVie Wants Hypertension Drug Antitrust Row Sent To NJ

Law360 (November 2, 2020, 8:29 PM EST) -- AbbVie Inc. and other pharmaceutical companies told a New York federal court Friday that lawsuits alleging they paid off competitors to delay generic competition for blood pressure drug Bystolic should be moved to New Jersey, the nation's "pharmaceutical epicenter," where most of the defendants and witnesses are based.

In a brief seeking a transfer of venue, the drugmakers said that most of the defendants and all of the witnesses in the five complaints brought by direct purchasers reside in the Garden State.

The complaints allege that AbbVie Inc. and subsidiaries under the Allergan and Forest Laboratories names used reverse payments —...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!